For the first time since 2016, Health and Human Services (HHS) released a report detailing the progress made in improving “meaningful access to language assistance services” for individuals who are considered to have limited English proficiency (LEP). The report was based off of Executive Order 13985 “Advancing Racial Equity and Support for Underserved Communities Through the Federal Government” and Executive Order 14012 “Restoring Faith in Our Legal Immigration Systems and Strengthening Integration and Inclusion Efforts for New Americans”. Collectively, these orders aimed to ease access to government services (that assist in overcoming barriers in federal programs) and formulate ways to encourage inclusion and integration of LEP individuals into the American democracy. Based on the 2022 HHS Equity Action Plan, successes over the past year were detailed. There was an increased ease of access to meaningful language tools in an individual’s preferred language via websites, listserv announcements, and public outreach material, something that was crucial during the Public Health Emergency.
However, HHS did receive a complaint alleging 19 states failed to provide individuals with meaningful access to their “COVID testing, inoculation, and treatment programs.” As a result, the Office for Civil Rights (OCR) addressed the complaint by teaming up with the Department of Homeland Security (DHS) and the Federal Emergency Management Agency (FEMA) to offer webinars about the importance of language access during emergency situations.
Also included in the report was a roadmap to further equal access to meaningful language assistance services. It details a need to eliminate the barriers in accessing language in core areas, including internet and telephone access, access to programs and activities, and federal funds used to provide the needed language services.
OCR also relaunched the Department’s Language Access Steering Committee on October 11, 2022. The committee will focus on implementing goals of the Equity Plan via language access quality assessments, summarizing the report findings to the Secretary on an annual basis. There is also the creation of a HHS Language Access Coordinator position, with the goal to set up a centralized language access center hub for HHS, update and revise HHS’s 2013 Language Access Plan, and take steps to address problems identified in OCR investigations of LEP grievances filed against HHS.
This report affirms how serious federal agencies are in supporting those individuals who are considered to have limited English proficiency. Likewise, PAAS National® aims to support our members in being culturally competent in how services are provided. Inquire about PAAS’ Cultural Competency training and the PAAS Care ModelTM to ensure your pharmacy is adherent to federal requirements.
PAAS Tips:
Invoice Audits Are on the Rise – Are You Prepared for Success?
Most pharmacies have grown accustomed to desk audits and providing copies of prescriptions, signature logs, and even copay collection records to PBMs upon request. Additionally, many pharmacies can recount their most recent experience with an onsite auditor visiting their pharmacy and the numerous questions related to operations, policies & procedures, and credentialing. However, not as many pharmacies have experienced an invoice audit – the stakes are higher and honest mistakes can lead to very expensive lessons in the process.
PAAS National® analysts have helped our members navigate countless invoice audits. Our analyst team is here to assist you through the audit process from start to finish and that includes getting things done correctly long before the audit ever comes your way. Follow the tips below to have the most success.
PAAS Tips:
Billing Test Claims? It Can Cost You!
We have all been there – a prescriber calls the pharmacy to find out which prescription from a therapeutic category will be the most cost-effective for the patient. Without access to a plan formulary, the only way you can easily do this for the prescriber is to bill claims to the insurance one by one. Not only is this a time-consuming practice, it can also be costly because “test claims” are prohibited by most third-party payers.
Why would something that seems beneficial to a patient be prohibited? Unfortunately, test claims have been used by bad actors to maximize reimbursement from PBMs, often to the detriment of the plan, and even the patient. In a real-world example, a Florida pharmacy owner was recently convicted on two counts of soliciting and receiving illegal health care kickbacks and three counts of offering and paying illegal health care kickbacks. He was caught when billing test claims to maximize his reimbursement, then paying millions in kickbacks based on a percentage of the reimbursement to those willing to prescribe the most expensive drugs. He is currently awaiting sentencing which could include a maximum of 10 years in prison for each kickback count.
Another reason test claims are prohibited is because a pharmacy may forget to reverse a claim after testing it and receive payment for a prescription that does not exist, was not prescribed, purchased, or dispensed. This can financially impact the plan and can lead to mistakes and confusion for the patient regarding deductibles and coinsurance.
PAAS Tips:
MATE Training for Buprenorphine Prescribers
Historically, buprenorphine prescriptions with an indication of opioid dependence were an easy recoupment when an X-DEA number wasn’t included on the hardcopy. However, as discussed in our February 2023 Newsline article, XDEA Numbers Have Been NiXed…but Not the Training, X-DEA numbers are no longer required due to the Mainstreaming Addiction Treatment (MAT) Act, found in Section 1262 of the “Consolidated Appropriations Act of 2023”. Instead, there are now training requirements for DEA registrants before being able to prescribe buprenorphine prescriptions. Beginning on June 27, 2023, Section 1263 of the “Consolidated Appropriations Act of 2023”, the Medication Access and Training Expansion (MATE) Act, requires all new or renewing DEA registrants to have met at least one of the following requirements when submitting their DEA registration application:
How does this relate to your pharmacy?
PAAS Tips:
Seeing Too Many or Repeated Prescription Validation Requests – Take Action!
In our February 2023 Newsline article, PBM Prescription Validation Requests Rose Nearly 20% in 2022, we mentioned that while the validation requests are a nuisance, they can work to the pharmacy’s benefit. Because the PBM is looking at the claim before payment is received, pharmacies can avoid incorrectly refilling a medication if an error is detected and potentially correct a billing error on the date that it is being reviewed. This can prevent large financial recoupments upon a future audit. These requests can also be very frustrating when the claim reviews are repetitious, and no billing errors are found creating work for the pharmacy without any need to correct the claim. See the PAAS tips below for best practices on how to track and manage duplicate or high numbers of validation requests.
PAAS Tips:
Are You Missing Audit Communications?
PAAS National® analysts have recently seen many PBMs and audit contractors send communications, including audit letters, to network pharmacies via email instead of facsimile or postal mail. In most cases, these emails are sent to the address on file via your NCPDP Pharmacy Profile.
One audit contactor, Conduent Payment Integrity Solutions, sends an email that includes an “acknowledgement” box within the email that pharmacies must click on to confirm receipt of the email. If the email is not acknowledged, then Conduent will send additional communications to confirm receipt.
PAAS Tips:
Incorrect NDC or NPI Billed? Humana Requires Corrections
Humana has recently sent out another round of audits where either an incorrect NDC number or National Provider Identifier (NPI) was billed. The claim went through the switch at the time of fill, so why is Humana auditing these claims years later, and how do they know these data fields had incorrect information?
These are likely Medicare claims that have been found to be invalid through retroactive validation of Prescription Drug Event (PDE) records by CMS. Humana must fix the incorrect information or face recoupment if it cannot be resolved.
An incorrect NDC is found when the NDC on the claim is billed before that NDC’s marketing start date, after the marketing end date, or not on the Food and Drug Administration’s (FDA) NDC Structured Product Labeling (SPL) Data Elements (NSDE) list. A pharmacy should not have access to a specific NDC before the marketing start date. The marketing end date will be the expiration date of the last lot manufactured of that NDC, so a pharmacy should not be filling that NDC any longer if following proper out-date procedures.
An incorrect NPI is found when a pharmacy inadvertently bills a claim under the wrong prescriber or when the PBM believes the prescriber billed does not have prescriptive authority. Many times, this happens when two practitioners in the area have the same first and last name. If the NPI billed does not have prescribing authority (e.g., occupational therapist, psychologist, or registered nurse), the claim could flag for further review. Some states may allow certain practitioners to have prescriptive authority that may not be allowed in other states (e.g., certified nurse midwives). In these cases, the pharmacy must prove the practitioner has prescribing authority in the state, usually through searching a state license database.
In both of these cases, Humana wants the pharmacy to investigate what happened to correct the claim. Humana knows that the claims may be too old to be corrected by the pharmacy, so they simply want the pharmacy to write in the correct information on the Claim Detail Sheet and send it back to Humana for them to correct (i.e., figure out which NDC was in stock on that date or which NPI should have been billed).
PAAS Tips:
At Your Own Risk: “Use as Directed”
How many times have you received a prescription for a bowel prep, starter pack, or pre-packaged taper where the directions simply state, “Use as Directed?” It is common for pharmacies to receive these medications, type “Use as Directed” for the patient label, bill the most common days’ supply, and move on. Unfortunately, this practice can lead to audit recoupment since there is no mathematical way to calculate the days’ supply for the claim without further clarification.
When receiving a “Use as Directed” prescription, you must contact the prescriber to find out if the patient is to follow the package directions or if the prescriber had directed the patient to take it in a different manner, possibly off-label. Once clarified, you can make a clinical note on the prescription and update the patient’s label with the specific directions or “use as directed per package.” These simple actions will save a lot of headaches when the next audit is sent.
PAAS Tips:
HHS Reports Successes in Access to Meaningful Language Assistance Services
For the first time since 2016, Health and Human Services (HHS) released a report detailing the progress made in improving “meaningful access to language assistance services” for individuals who are considered to have limited English proficiency (LEP). The report was based off of Executive Order 13985 “Advancing Racial Equity and Support for Underserved Communities Through the Federal Government” and Executive Order 14012 “Restoring Faith in Our Legal Immigration Systems and Strengthening Integration and Inclusion Efforts for New Americans”. Collectively, these orders aimed to ease access to government services (that assist in overcoming barriers in federal programs) and formulate ways to encourage inclusion and integration of LEP individuals into the American democracy. Based on the 2022 HHS Equity Action Plan, successes over the past year were detailed. There was an increased ease of access to meaningful language tools in an individual’s preferred language via websites, listserv announcements, and public outreach material, something that was crucial during the Public Health Emergency.
However, HHS did receive a complaint alleging 19 states failed to provide individuals with meaningful access to their “COVID testing, inoculation, and treatment programs.” As a result, the Office for Civil Rights (OCR) addressed the complaint by teaming up with the Department of Homeland Security (DHS) and the Federal Emergency Management Agency (FEMA) to offer webinars about the importance of language access during emergency situations.
Also included in the report was a roadmap to further equal access to meaningful language assistance services. It details a need to eliminate the barriers in accessing language in core areas, including internet and telephone access, access to programs and activities, and federal funds used to provide the needed language services.
OCR also relaunched the Department’s Language Access Steering Committee on October 11, 2022. The committee will focus on implementing goals of the Equity Plan via language access quality assessments, summarizing the report findings to the Secretary on an annual basis. There is also the creation of a HHS Language Access Coordinator position, with the goal to set up a centralized language access center hub for HHS, update and revise HHS’s 2013 Language Access Plan, and take steps to address problems identified in OCR investigations of LEP grievances filed against HHS.
This report affirms how serious federal agencies are in supporting those individuals who are considered to have limited English proficiency. Likewise, PAAS National® aims to support our members in being culturally competent in how services are provided. Inquire about PAAS’ Cultural Competency training and the PAAS Care ModelTM to ensure your pharmacy is adherent to federal requirements.
PAAS Tips:
Remember to Maintain and Provide Complete Clinical Notes!
Physical storage for keeping paper records comes at a space premium for many pharmacies. With the significant increase of electronic prescriptions, many pharmacies are choosing not to keep printed copies, where allowed by state/federal law. Pharmacies must be very diligent with electronic documentation when electronically storing their prescriptions.
PAAS National® has always recommended four elements for clinical notations:
In the past, pharmacies would simply document this information on the prescription. If the prescription was audited, this information would be readily visible for the auditor’s review. If pharmacies are not printing electronic orders, these clinical notations are still imperative, but typically documented electronically. The same four elements are recommended for electronic notes, but preferably with date/time stamped user information.
During an audit, pharmacies must review prescriptions closely for any clinical notations, and ensure they are included with their documentation. Consult with your software vendor on the best ways to utilize the electronic notes field and how to easily access if needed.
Pharmacies that print images for audits must remember that faxed, written or telephone orders may have clinical notes written on the hard copy that did not get re-scanned in. Missing these clinical notations could lead to recoupments as the auditor can only see the information provided to them.
PAAS Tips:
Dispense in Original Container – Know the Audit Risks
PAAS National® analysts want to remind pharmacies of the audit risks when medications are dispensed outside manufacturer storage/dispensing requirements. PBMs can easily identify claims billed for a quantity that does not match the package size for a particular NDC, making them an easy target for recoupment.
Manufacturers submit storage/dispensing requirements to the FDA, which in turn appears on the package and in the package insert. These requirements may be based on light or moisture sensitivity or simply that the product has not been tested outside the original container. Pharmacies can utilize the DailyMed website to find product labeling information; however, be aware that variations in labeling precautions exists. PAAS has spoken with the FDA about inconsistent verbiage for precautions, even amongst products from the same manufacturer. While standardization would provide clarity and be helpful for all dispensing pharmacists, the FDA defers this language choice to the manufacturers.
Another twist on quantity dispensed not divisible by package size is diabetic test strips – the NDC must match what you are dispensing. Claims billed for the 100-count box, but quantity billed is not divisible by 100 (e.g., 150) can result in a partial recoupment.
PAAS has created a chart for the most common medications targeted on audit for dispensing outside manufacturer requirements. Download the Dispense in Original Container Chart from the PAAS Member Portal and access many other Proactive Tips, Days’ Supply Charts, On-Demand Webinars and additional resources that further assist PAAS members and their staff.
While on the website, check out PAAS’ Upcoming Events for locations you can find us. Stop by our booth to say “hi” and pick up our new 5×7 inch, laminated Dispense in Original Container Chart and Considerations for Billing Insulin Vials magnet!